TPI 1100
Alternative Names: PD 3 project; PXS TPI 1100; TPI-PD3 projectLatest Information Update: 13 Dec 2023
At a glance
- Originator Topigen Pharmaceuticals
- Developer Syntara Limited; Topigen Pharmaceuticals
- Class Antisense oligonucleotides
- Mechanism of Action Phosphoric diester hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Suspended Chronic obstructive pulmonary disease